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Abstract
Background: Sternal wound infection remains a serious potential complication after cardiac surgery. A recent
development for preventing wound complications after surgery is the adjunctive treatment of closed incisions with
negative pressure wound therapy. Suggested mechanisms of preventive action are improving the local blood flow,
removing fluids and components in these fluids, helping keep the incision edges together, protecting the wound
from external contamination and promoting incision healing. This work reports on our initial evaluation and clinical
experience with the Prevena™Incision Management System, a recently introduced new negative pressure wound
therapy system specifically developed for treating closed surgical incisions and helping prevent potential
complications. We evaluated the new treatment on sternal surgical incisions in patients with multiple co-
morbidities and consequently a high risk for wound complications.
Methods: The Prevena™incision management system was used in 10 patients with a mean Fowler risk score of
15.1 [Range 8-30]. The negative pressure dressing was applied immediately after surgery and left in place for 5
days with a continuous application of -125 mmHg negative pressure. Wounds and surrounding skin were
inspected immediately after removal of the Prevena™ incision management system and at day 30 after surgery.
Results: Wounds and surrounding skin showed complete wound healing with the absence of skin lesions due to
the negative pressure after removal of the Prevena™ dressing. No device-related complications were observed. No
wound complications occurred in this high risk group of patients until at least 30 days after surgery.
Conclusions: The Prevena™system appears to be safe, easy to use and may help achieve uncomplicated wound
healing in patients at risk of developing wound complications after cardiothoracic surgery.
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Background
The incidence of sternal wound infection (SWI) after
cardiac surgery ranges from 1-10% depending on the
definitions applied and the subset of the population ana-
lyzed [1,2]. Despite the use of prophylactic systemic
antibiotics, postoperative sternal wound infection still
occurs in some circumstances and it continues to be a
serious problem after surgical cardiac procedures. Ster-
nal wound infection is associated with significant reduc-
tion in quality of life, additional expenses increased
length of stay in the hospital and in an increased mor-
tality during the first year [1,3-5]. It has been estimated
that SWI may almost triple the costs for patients under-
going coronary artery bypass graft [4-8]; additional costs
of up to 80.000 USD have been reported [9].
It has been shown that there is an increased risk of
infection in patients presenting with diabetes, smoking,
obesity, harvesting of bilateral internal mammary
arteries, increasing number of grafts, peripheral vascular
disease, renal failure, chronic pulmonary disease,
increased duration of mechanical ventilation and preo-
perative malnutrition [3,10-13]. High-risk patients can
be identified using for example the Fowler score
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help prevent this type of complications [13].
Various studies have focused on techniques or devices
to reduce SWI such as microbial sealant prior to surgery
[14], different methods of sternal closure (Robicsek
technique [15], rigid-plate sternal fixation [16], nitinol
clips [17]), different methods of skin closure (intrader-
mic closure [18], skin staples [19], liquid skin adhesive
[20], prophylactic gentamycin-collagen sponge [21],
topical application of autologous blood products [22],
hydrocolloids [23], growth factors [24]) or a combina-
tion of them. All these techniques have showed good
results reducing incidence of mediastinitis and reducing
the length of stay in the hospital. Unfortunately, no one
has achieved widespread use due to the absence of
strong evidence based on well performed controlled
clinical studies and due to the increased costs.
Based on the worldwide positive experience with nega-
tive pressure wound therapy (NPWT) for the manage-
ment of soft tissue defects and the proposed
mechanisms of action several authors have used the
beneficial effects of NPWT for the management of post-
operative incision wounds [25-31].
As a result of the increased use of NPWT for (prophy-
lactic) treatment of closed incisions the manufacturer of
the vacuum assisted closure system (VAC). Therapy sys-
tem recently developed a negative pressure system spe-
cifically for treatment of closed incisions. In this study
we present our initial experience with the new Preve-
na™Incision Management System (Kinetic Concepts
Inc, San Antonio, TX) in patients, which are at high risk
for developing surgical wound complications after cardi-
othoracic surgery. Our objective was to test the ease of
use and safety of the new device in this indication. Sec-
ondary endpoints were the occurrence of complications
to the wound and the intact surrounding skin.
Methods
This prospective cohort study was conducted between
January 2011 and March 2011 at the Hospital Universi-
tari Germans Trias i Pujol in Badalona, Spain. A total of
97 cardiothoracic procedures were performed during
this 3 months period. Ten patients who presented an
increased estimated risk for postoperative SWI based on
the risk score described by Fowler [13] were consecu-
tively preoperatively elected for treatment with the Pre-
vena™ incision management system. Patients were
selected if reached a minimum preoperative Fowler
score of 7 (estimated probability of infection of 2.1%).
The median estimated risk for SWI was 12.5 points,
with a mean of 15.1 and a standard deviation of 6.8.
More background patient characteristic can be found in
table 1. Based on the Fowler estimated probability of
infection score the average risk of infection for these 10
patients was 6.4% (range 2.3% - 16.2%) [13].
Immediately after the surgical procedure all incisions
were closed in a standard fashion with 6 to 9 stainless
steel wires, one-layer double suture technique with a 1/0
monofilament absorbable suture (Ethibond
®,E t h i c o n ,
Norderstedt, Germany) for the muscular and
Table 1 Patient characteristics
PATIENT AGE,
GENDER
PREOPERATIVE VARIABLES OPERATION FOWLER
SCORE
PROBABILITY OF
INFECTION
17 3 y ,
male
Diabetes, Chronic lung disease, Myocardial infarction CABGx3 (LIMA-
LAD)
11 3.5
26 7 y ,
male
Diabetes, Chronic lung disease, BMI 30 to 40 kg/m2, Peripheral vascular
disease
CABGx1 LIMA-LAD
AVR
18 8.5
36 3 y ,
male
Chronic lung disease, Peripheral vascular disease, Myocardial infarction CABGx3 (LIMA and
RITA)
8 2.3
47 8 y ,
female
Diabetes, Renal failure, BMI 30 to 40 kg/m2, Peripheral vascular disease CABGx1 (LIMA-
LAD) and AVR
23 12.5
56 5 y ,
female
Diabetes, Renal failure, BMI 30 to 40 kg/m2, Peripheral vascular disease,
Myocardial infarction, Cardiogenic shock
CABGx1 (LIMA-
LAD) and MVR
30 16.2
66 2 y ,
male
Diabetes, Peripheral vascular disease, Myocardial infarction CABGx3 (LIMA and
RITA)
9 2.7
77 2 y ,
female
Diabetes, Peripheral vascular disease, Myocardial infarction CABGx3 (LIMA-
LAD)
13 4.5
86 2 y ,
female
Diabetes, BMI 30 to 40 kg/m2, Peripheral vascular disease, Myocardial
infarction
CABGx3 (LIMA and
RITA)
15 6.0
96 5 y ,
female
Diabetes, Peripheral vascular disease, Myocardial infarction CABGx3 (LIMA and
RITA)
12 4.0
10 55 y,
male
Diabetes, BMI 30 to 40 kg/m2, Peripheral vascular disease, Myocardial
infarction
CABGx3 (LIMA and
RITA)
12 4.0
y, year; BMI, body mass index; CABG, coronary artery bypass graft; AVR, aortic valve replacement; MVR, mitral valve replacement; LIMA, left internal mammary
artery; RITA, right internal mammary artery; LAD, left anterior descending coronary artery.
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suture with 3/0 absorbable suture for the dermis
(Monocryl
®, Ethicon, Norderstedt, Germany). The Pre-
vena™ incisional dressing system was applied in the
operating theatre immediately after wound closure. The
24 cm long Prevena™ dressing was placed over the
closed incision and negative pressure was applied (Fig-
u r e1 ) .T h eP r e v e n a ™ dressing system was always used
for 5 days. Patients were monitored daily for symptoms
of wound infection. Wounds were inspected immedi-
ately after removal of the Prevena™ therapy system and
at day 30 after surgery.
This Prevena™ Incision Management system consists
of a suction unit with a small canister for fluid collec-
tion, a tubing and a sponge dressing with non adherent
layer and semipermeable adhesive drape. The dressing
contains ionic silver (0.019%) to prevent bacterial
growth in the dressing. The system is supplied with a
carrying case to minimize effects on patient mobility.
The system when applied and activated maintains a
closed environment and removes fluids via the applica-
tion of negative pressure therapy.
According to the manufacturer in order to get a maxi-
mum benefit, the Prevena™™ Incision Management
System should be applied immediately after the surgery
to closed surgical incisions. The incision site must be
cleaned and dried to ensure proper fixation of the trans-
parent adhesive drape, chest drainage tubes and pain
management control devices should be located away
from dressing application site to prevent air leakage via
these materials. The Prevena™ dressing tube is con-
nected to the Prevena™ suction unit by the canister for
fluid collection. The vacuum therapy unit produces a
negative pressure of -125 mmHg and its lifespan is 8
days. Light showering is permitted. It must be continu-
ously active for a period between 3 and 5 days and with
a maximum of 8 days. The Prevena™ Incision Manage-
ment System should not be used to treat open or dehis-
cent surgical wounds or in patients with a incision that
produces an excessive amount of exudate which may
Figure 1 The clinical application of the Prevena™ Incision Management System.
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mum capacity 45 mL). Other NPWT Systems should be
considered for treating these wounds. It’s use in patients
with sensitivity to silver is contraindicated, and it should
be avoided in case of ischemia in the incision area,
inadequate hemostasis of the incision and cellulitis of
the incision area. Written informed consent was
obtained from the patient for publication of this case
report and accompanying images. The present clinical
research was carried out in compliance with the Hel-
sinki Declaration. A copy of the written consent is avail-
able for review by the Editor-in-Chief of this journal.
Results and Discussion
Application of the Prevena™ dressing system immedi-
ately after wound closure was uncomplicated and took
only a few minutes. In two cases, after starting the nega-
tive pressure therapy, the audio and visual alarms were
activated due to an air leak. In both cases the incision
dressing was partially applied over the chest drainage
tube and a small bleeding in that area produced the loss
of the vacuum in the dressing. We removed the exces-
sive dressing and we resealed the Prevena™ system with
patch strips. In both cases this resolved the problem and
the vacuum therapy continued to work properly until its
removal at day 5. In the other 8 cases no leakage or
other alarms were reported.
Upon removal of the dressing after 5 days of continu-
ous Prevena™ therapy the wound healing was complete
in all patients. No wounds developed complications
such as infection. Re-evaluation of the wounds at day 30
again showed complete wound healing with absence of
wound infections.
Wound repair is an orchestra of biological and mole-
cular events such as cell migration, proliferation and of
extracellular matrix depositioning and remodeling. Cer-
tain pathophysiologic and metabolic conditions can alter
this normal course of events so that healing is impaired
or delayed. This may result in acute or chronic non
healing wounds.
The risk of developing a surgical wound infection is
largely determined by 3 factors: 1) the amount and type
of microbial contamination of the wound, 2) the condi-
tion of the wound at the end of the surgical procedure,
and 3) host susceptibility, which is the patient’s intrinsic
ability to deal with microbial contamination. These fac-
tors interact in a complex manner. Measures intended
to prevent surgical wound infections are directed to all
3 factors. Since most infections are acquired in the
operating room and in the intensive care unit, measures
for prevention should be addressed to influence the
practices of the entire surgical team.
Measures aimed at preventing microbial contamina-
tion of the wound are the following: preparation of the
patients before operations (treating active infections,
maintaining a short preoperative stay in the hospital,
antiseptic skin preparation), preparation of the surgical
team (scrubbing hands with sterile materials), prepara-
tion and maintenance of the operating room environ-
ment (reducing airborne microorganisms), operative
technique (surgery duration, wound drainage, wound
closure, strict glucose control), wound care (wound
dressing), prophylactic antimicrobials, protection of
patients from other infected patients or personnel, sur-
veillance and classification.
Intravenous antibiotic prophylaxis in cardiac surgery
achieves up to a five-fold reduction in surgical wound
infections rate [32]. However, the use of broad-spectrum
antibiotics for surgical prophylaxis adds to the selective
pressure driving the development of resistant pathogens
[32]. It has been reported that patients with antibiotic
resistance bacteria have a higher mortality, prolonged
hospitalization and increased health-care costs com-
pared with those infected with non-resistant pathogens
[33].
Various studies have focused on techniques for redu-
cing SWI after cardiac surgery such as microbial sealant
prior to surgery, different methods of sternal closures,
different methods of skin closures, and a combination of
them.
However, no one has achieved widespread use due to
the absence of strong evidence based on well performed
controlled clinical studies.
Two articles were published recently showing some
evidence on the proposed mechanisms of action of the
Prevena™ dressing system. Wilkens et al [29] using a
finite element model showed that the negative pressure
applied with this system decreased lateral tissue stresses
and changed the direction of tissue stresses to a distri-
bution that is typical for intact tissues. Bench testing
results indicated that the dressing bolsters appositional
forces at the incision. Kilpadi et al [30] showed in a por-
cine study that using the Prevena™ dressing system
hematoma and seroma formation was reduced and that
the negative pressure dressing increased lymph clear-
ance. In a recently published RCT Pachowsky et al [31]
studied the incidence and volume of seromas when the
Prevena™ incision management system was applied to
surgical wounds after total hip arthroplasty procedures
and compared these with the use of standard wound
treatment after THA. Similarly to the porcine study also
this RCT in humans showed a significant reduction in
seromas and in seroma volume upon application of the
Prevena™ incision management system.
In four recent studies a modified topical Vacuum
Assisted Closure system was used and a non-adherent
layer was applied between the foam and the incision
and surrounding intact skin.
Colli Journal of Cardiothoracic Surgery 2011, 6:160
http://www.cardiothoracicsurgery.org/content/6/1/160
Page 4 of 6Stannard et al [25] published results of a randomized
controlled trial (RCT) demonstrating decreased drainage
and improved wound healing following negative pres-
sure wound therapy treatment of both hematomas and
severe fractures. In another RCT Stannard et al [26]
compared the effect of NPWT at -125 mmHg to stan-
dard postoperative dressings used in closed incisions fol-
lowing high-energy trauma. Two-hundred-sixty-two
patients were included in the study, of those 141 were
randomized to NPWT and 121 were randomized to
control treatment. The incidence of wound dehiscences
and infections was found to be lower in the NPWT
g r o u pc o m p a r e dt oc o n t r o lg r o u p( p<0 . 0 3a n dp<
0.02, respectively). Atkins et al [27] reported results of a
retrospective review using NPWT at -125 mmHg for 4
days on 57 patients at high risk for sternal wound infec-
tions after cardiac surgery. These patients were com-
pared to 213 patients without infection risk of and
managed with standard of care procedures. The authors
observed no complications in the NPWT group and one
infection in the control group, concluding that the
NPWT was easily applied and well tolerated and should
be considered for patients with an increased risk for
sternal wound infections. Gomoll et al [28] reported a
case series of 35 patients of high-risk patients following
orthopedics surgery. NPWT was applied at -75 mmHg
for 3 days. No infections were observed after a mini-
mum follow-up of 3 months.
The Prevena™ Incision Management System repre-
sents the first dressing system specifically designed to
help prevent the development of healing complications
such as infection and dehiscence. In particular the use
of Prevena™ intends to improve the incisional healing
with an innovative and effective negative pressure dres-
sing via protection from external contamination, keeping
the wound edges together, equalizing strain in the tissue
and via application of the beneficial effects of the
NPWT therapy (stimulation of cell proliferation, reduc-
tion of inflammatory mediators, increasing arterial and
subcutaneous oxygen partial pressure, reduction of the
wound stress) already demonstrated over the past 15
years of clinical experience with this technology.
This report presents our initial application and evalua-
tion of the Prevena™ Incision Management System in
our institution and represents the first report in cardiac
surgery patients in Europe on this new class II device.
The results observed using the Prevena™ system are
encouraging. In this very high risk for SWI group of
patients there were no early or late wound infections.
We are aware that the small number of patients is a
limitation of the present evaluation. Due to the fact that
we did not perform a large controlled clinical trial we
are not able to identify the Prevena™ system as the
only factor that could explain the observed favorable
results.
We estimate that the Prevena™ Incision Management
System may play an important role in patients present-
ing a preoperative or intraoperative high risk of SWI
(double mammary harvesting, obesity, severe chronic
obstructive pulmonary disease, malnutrition, long hospi-
tal stay), together with other clinical strategies such as
weight loss and/or smoking, interventions targeting Sta-
phylococcus aureus, including nasal decolonization and
vaccines. Due to the high costs of sternal wound infec-
tions and the increased risk in this population additional
expenditures to help prevent complications might be
justified. More robust controlled clinical and economical
studies are required to assess the clinical and cost-effec-
tiveness of the Prevena™ Incision Management System
and to determine which patients would benefit most
from this new specialized wound technology.
Conclusion
In conclusion the preliminary results observed in our
center are encouraging; however, our data are insuffi-
cient to at this moment recommend a widespread use of
this technology. Our data can serve as a basis for more
definitive studies to determine which patients and
wound types could benefit from this therapy.
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